860374-83-0 Usage
Description
3-Butenylethylmalonic Acid Diethyl Ester is an organic compound that serves as an intermediate in the synthesis of various pharmaceuticals and chemicals. It is characterized by its unique molecular structure, which includes a butenylethylmalonic acid backbone and two diethyl ester groups. 3-ButenylethylMalonic Acid Diethyl Ester plays a crucial role in the production of certain drugs, particularly barbiturates, due to its ability to undergo specific chemical reactions.
Uses
Used in Pharmaceutical Industry:
3-Butenylethylmalonic Acid Diethyl Ester is used as a key intermediate in the synthesis of barbiturates for the pharmaceutical industry. Barbiturates are a class of drugs that have sedative-hypnotic, anticonvulsant, and anesthetic properties. They are used to treat conditions such as insomnia, seizures, and as pre-anesthetic medications before surgical procedures.
As an intermediate, 3-Butenylethylmalonic Acid Diethyl Ester is involved in the chemical reactions that lead to the formation of barbiturate compounds. Its presence in the synthesis process is essential for the production of these drugs, which have a wide range of medical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 860374-83-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,0,3,7 and 4 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 860374-83:
(8*8)+(7*6)+(6*0)+(5*3)+(4*7)+(3*4)+(2*8)+(1*3)=180
180 % 10 = 0
So 860374-83-0 is a valid CAS Registry Number.
860374-83-0Relevant articles and documents
Metabolism of 2-ethylhexanol administered orally and dermally to the female Fischer 344 rat
Deisinger,Boatman,Guest
, p. 429 - 440 (2007/10/03)
1. Excretion balance studies were conducted with 2-ethylhexanol (2-EH) in female Fischer 344 rats following single high (500 mg/kg) and low (50 mg/kg) oral doses of [14C]2-EH, following repeated oral dosing with unlabelled 2-EH at the low level, following dermal exposure for 6 h with a 1 g/kg applied dose of [14C]2-EH, and following a 1 mg/kg i.v. dose of [14C]2-EH. 2. The high, low and repeated low oral dose studies with 2-EH showed similar excretion balance profiles of [14C], with some evidence of metabolic saturation at the high dose. 3. No evidence of metabolic induction was seen following the repeated low oral dosing. 4. All of the oral doses were eliminated rapidly, predominantly in the urine during the first 24 h following dosing. 5. The dermal dosing resulted in only about 5% absorption of the 1 g/kg dose, with the major portion of the dose recovered unabsorbed from the dermal exposure cell at 6 h. 6. Urinary metabolites eliminated following the oral and dermal doses were predominately glucuronides of oxidized metabolites of 2-EH including glucuronides of 2-ethyladipic acid, 2-ethylhexanoic acid, 5-hydroxy-2-ethylhexanoic acid and 6-hydroxy-2-ethylhexanoic acid.
